Maintenance of epigenetic integrity during nuclear reprogramming
Maintenance of epigenetic integrity during nuclear reprogramming
批准号:
8765752
负责人:
Matthias Stadtfeld
金额:
$33.11万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-15 至 2019-06-30
关键词:
AdoptedAdultAffectAscorbic AcidBenefits and RisksBindingBioinformaticsCell LineCell physiologyCellsChemicalsChromatinClinicalDNADefectDerivation procedureDisease modelEmbryoEnzymesEpigenetic ProcessExhibitsExposure toGene ClusterGene ExpressionGene TargetingGenerationsGenesGerm CellsGoalsGoldHumanHypermethylationIn VitroIndividualLeadLinkMaintenanceMediatingMemoryMinorityModelingMolecularMolecular AbnormalityNormalcyPatientsPatternPhysiologicalPluripotent Stem CellsProcessPropertyProtocols documentationRecurrenceReporterResearchResearch Project GrantsRiskSignal PathwaySomatic CellStem cellsSystemTechnologyTissuesTransgenic MiceWorkcell typechromatin remodelingdesignembryonic stem cellepigenomegenome wide association studygenome-widehuman diseaseimprintimprovedin vivoinduced pluripotent stem cellinsightmouse modelnovelnuclear reprogrammingpluripotencypreventprotective effectpublic health relevanceresearch studytranscription factor
中文摘要
描述(由申请人提供):诱导多能干细胞(iPSC)可以通过强制表达确定的转录因子从成体组织中衍生。这个过程被称为重编程。由于iPSC可以分化成任何成体细胞类型,并且与它们所来源的个体完全匹配,因此重编程技术从根本上改变了疾病建模的能力,并带来了个性化细胞疗法的新概念。然而,iPSCs在重编程过程中可能会获得有害的表观遗传异常。这种情况发生的方式仍然知之甚少。在一个重要的原理证明中,我们先前已经表明,印迹Dlk 1-Dio 3簇的DNA超甲基化是一种常见的iPSC正常现象,可以通过在含有抗坏血酸的培养基中重编程来有效地防止,抗坏血酸是经常用于提高重编程效率的几种化合物之一。该研究项目的目标是对复发性基因特异性和全基因组表观遗传iPSC异常以及重编程增强化学物质如何预防或触发其发生进行机械理解。利用独特的转基因小鼠模型,我们将追求以下三个目标。1)我们将确定负责异常超甲基化的Dlk 1-Dio 3以及那些参与介导抗坏血酸对该基因簇的保护作用的基因。2)我们将进行全基因组研究,以确定几种常用的重编程增强化学物质如何在iPSCs形成过程中促进染色质重塑,以及这与在此过程中维持表观遗传完整性的关系。3)我们将系统地鉴定iPSCs的分子和功能特性,这些特性在重编程过程中受到暴露于特定常用化合物的持久影响。总之,这些实验将更好地理解为什么表观遗传异常被引入iPSCs,以及它们的发生如何与成功重编程的表观遗传重塑相关。此外,我们的工作将揭示化学重编程的可能益处和风险,从而有助于获得高质量的人类iPSCs,可能仅使用化学化合物。
英文摘要
DESCRIPTION (provided by applicant): Induced pluripotent stem cells (iPSCs) can be derived from adult somatic tissues by the enforced expression of defined transcription factors. This process is referred to as reprogramming. As iPSCs can differentiate into any adult cell type and are fully matched to the individual they were derived from, reprogramming technology has radically altered the ability to model disease and led to new concepts for personalized cellular therapies. However, iPSCs can acquire detrimental epigenetic abnormalities during the reprogramming process. This occurs in manners that remain poorly understood. In an important proof-of-principle we have previously shown that DNA hypermethylation of the imprinted Dlk1-Dio3 cluster is a frequent iPSC normality that can be efficiently prevented by reprogramming in media containing ascorbic acid, one of several chemical compounds frequently used to increase reprogramming efficiencies. The goal of this research project is to develop a mechanistic understanding of recurrent gene-specific and genome-wide epigenetic iPSC abnormalities and for how reprogramming enhancing chemicals can prevent or trigger their occurrence. Using unique transgenic mouse models, we will pursue the following three aims. 1) We will identify the genes responsible for aberrant hypermethylation of Dlk1-Dio3 as well as those involved in mediating the protective effect of ascorbic acid on this gene cluster. 2) We will conduct genome-wide studies to determine how several frequently used reprogramming enhancing chemicals facilitate chromatin remodeling during iPSCs formation and how this relates to the maintenance of epigenetic integrity during this process. 3) We will systematically identify molecular and functional properties of iPSCs that are affected in a lasting manner by exposure to specific frequently used chemical compounds during the reprogramming process. Together, these experiments will provide a better understanding of why epigenetic abnormalities are introduced into iPSCs and how their occurrence relates to epigenetic remodeling crucial for successful reprogramming. In addition, our work will reveal possible benefits and risks of chemical reprogramming and thereby aid the derivation of high-quality human iPSCs, possibly by the use of chemical compounds alone.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dissecting genetic determinants of epigenetic instability in pluripotent stem cells
-
批准号:10609911
-
项目类别:
-
资助金额:$39.91万
-
财政年份:2022
-
负责人:Matthias Stadtfeld
-
依托单位:
Maintenance of epigenetic integrity during nuclear reprogramming
-
批准号:9494624
-
项目类别:
-
资助金额:$32.18万
-
财政年份:2014
-
负责人:Matthias Stadtfeld
-
依托单位:
Maintenance of epigenetic integrity during nuclear reprogramming
-
批准号:9303421
-
项目类别:
-
资助金额:$32.19万
-
财政年份:2014
-
负责人:Matthias Stadtfeld
-
依托单位:
Transgenic models to investigate imprinted gene expression in somatic tissue
-
批准号:8686139
-
项目类别:
-
资助金额:$16.95万
-
财政年份:2013
-
负责人:Matthias Stadtfeld
-
依托单位:
海外基金